Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UMN's novel flu vaccine positive in early trial

This article was originally published in Scrip

Executive Summary

The Japanese venture UMN Pharmahas reported positive results from a Phase I/II trial with its novel pandemic flu vaccine UMN-0501. The company said responses had been observed in the low dose trial in 125 healthy male subjects, including with a non-aluminum adjuvant formulation, with no serious adverse reactions. It is now planning a larger Phase II trial at higher doses this year. The recombinant vaccine is manufactured using a baculovirus expression vector system and cultured insect cells to express the target haemagglutinin protein. This enables production times to be cut to around eight weeks, from six months or so for traditional egg-based methods (Scrip Online, June 11th, 2008). UMN-0501 already has orphan status in Japan.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts